| Old Articles: <Older 2031-2040 Newer> |
|---|
 |
The Motley Fool
May 31, 2005
Karl Thiel |
Is Eyetech Better Than It Looks? If you're a born contrarian with a little spare mad money lying around, this biotech could be worth buying at these levels.   |
The Motley Fool
May 27, 2005
Rich Duprey |
Glaxo's Flu Vaccine Booster The drug giant's return could give the U.S. flu vaccine market a shot in the arm. |
The Motley Fool
May 27, 2005
Nick Baker |
Mama Always Said You'd Go Blind Urban legends aside, what do new concerns about Viagra and Cialis mean for investors? |
The Motley Fool
May 27, 2005
Charly Travers |
Vertex's Cautious Optimism The company's innovative hepatitis C drug has made May a month to remember. Investors, take note. |
The Motley Fool
May 27, 2005
Stephen D. Simpson |
Once More With Merck Merck has had a busy spring, but are investors any better off? |
The Motley Fool
May 26, 2005
Stephen D. Simpson |
A Second Opinion on Medtronic Medtronic is a growth stalwart, but does valuation properly account for the challenges? |
The Motley Fool
May 26, 2005
Stephen D. Simpson |
Elan Holds Its Ground Elan clearly isn't throwing in the towel on Tysabri, but its fate is not solely in the company's hands. If you're pinning your hopes on a full return on this drug, you might be signing on for more risk than you really want. |
The Motley Fool
May 26, 2005
Stephen D. Simpson |
Patterson Gets Drilled Investors punish this dental distributor for a quarterly miss and lowered guidance. |
The Motley Fool
May 26, 2005
Brian Gorman |
Flu Vaccines' Unhealthy Competition The vaccine business is notoriously tricky. Given the nature of the business, respectable returns are predicated on high volumes. New competitors in the flu-fighting niche could make all companies worse off. |
The Motley Fool
May 26, 2005
Stephen D. Simpson |
PolyMedica's Second Act PolyMedica has a cash-rich legacy business, but growth will require new strategies. Investors, take note. |
| <Older 2031-2040 Newer> Return to current articles. |
